PTCT — PTC THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1070081 ·
Last close
$60.36
Market Cap
$5.04B
52W High
$90.87
52W Low
$58.80
ADV30
1,064,798
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 357,807,000 | 334,143,000 | 25,114,000 | -51,693,000 | 3,207,715,000 | 508,894,000 | 3,398,924,000 |
| Jun 2026 | 360,519,000 | 340,598,000 | 148,977,000 | 83,496,000 | 3,250,477,000 | 1,049,887,000 | 3,415,840,000 |
| Mar 2026 | 272,551,000 | 244,523,000 | 45,886,000 | -2,809,000 | 2,869,104,000 | 833,986,000 | 3,049,569,000 |
| Dec 2025 | 164,677,000 | 157,727,000 | -81,624,000 | -134,965,000 | 2,898,767,000 | 984,648,000 | 3,104,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,503,000
Investing CF
$-471,907,000
Financing CF
$536,004,000
CapEx
$-302,053,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,883,542,000
Inventory
$91,354,000
Receivables
$239,044,000
ST Investments
$1,179,195,000
EBIT TTM
$118,217,000
Pretax Income TTM
$-67,074,000
Interest Exp TTM
$185,291,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,155,554,048
EBITDA
$309,559,008
Free Cash Flow
$159,936,256
Enterprise Value
$5,823,869,952
Total Cash
$2,127,917,952
Total Debt
$2,941,637,120
Shares Out
83,544,284
Trailing EPS
$-0.65
Book Value
$-1.99
ROE
—
ROA
5.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,730,655,000 | 856,508,000 | 682,644,000 | 2,898,767,000 | 3,104,080,000 | -205,313,000 | 711,196,000 |
| Dec 2024 | 806,780,000 | -146,747,000 | -363,295,000 | 1,705,024,000 | 2,803,095,000 | -1,098,071,000 | -107,688,000 |
| Dec 2023 | 937,822,000 | -349,402,000 | -626,604,000 | 1,895,698,000 | 2,714,253,000 | -818,555,000 | -158,418,000 |
| Dec 2022 | 698,801,000 | -439,925,000 | -559,017,000 | 1,705,619,000 | 2,052,705,000 | -347,086,000 | -356,654,000 |
TTM Snapshot
Revenues TTM
$1,008,754,000
NetIncome TTM
$-38,382,000
OpCashFlow TTM
—
Assets (Latest)
$3,250,477,000
Forward EPS
$2.37
Max Pain — expiry 2027-01-15
max pain strike: $70.00 · spot: $60.23 · call oi: 11,657 · put oi: 1,101
Expected Move to 2027-01-15:
±$9.35
(15.52%) —
implied range
$50.88 –
$69.58
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LQDA | Liquidia Corp | $5.11B | $56.73 | — |
| TVTX | Travere Therapeutics, Inc. | $4.91B | $51.10 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.90B | $86.98 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
News headlines (Yahoo Finance, 1h cache)
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
2026-11-17 00:14 · Yahoo
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
2026-11-03 12:00 · Yahoo
PTC Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 13:00 · Yahoo
PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss
2026-10-31 17:12 · Yahoo
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 20:30 · Yahoo
PTC Therapeutics (PTCT) Q3 2026 Earnings Call Transcript
2026-10-30 15:00 · Yahoo
PTC Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
PTC Therapeutics Q3 Earnings Call Highlights
2026-10-30 01:14 · Yahoo
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-10-29 21:00 · Yahoo
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
2026-10-29 20:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.